论文部分内容阅读
目的研究配对盒基因9(Pax9)在非小细胞肺癌(NSCLC)患者血清中的表达及临床意义。方法采用酶联免疫吸附法(ELISA)检测35例NSCLC患者血清中Pax9的浓度,以42例肺良性病变(慢性阻塞性肺疾病、肺炎)患者和30例健康者作为对照,并分析Pax9的表达与NSCLC患者临床病理特征及预后的关系。结果 NSCLC患者血清中Pax9的浓度[(144.6±87.4)ng/ml]明显高于肺良性病变患者[(94.8±44.4)ng/ml]和健康者[(103.3±58.3)ng/ml],差异有统计学意义(P<0.05)。Pax9的表达水平与患者性别、年龄、吸烟史及淋巴转移等临床病理特征无关(P>0.05),但与肿瘤病理分型、TNM分期显著相关(P<0.05)。另外,Kaplan-Meier分析显示,Pax9高表达组患者的生存时间明显低于低表达组患者的生存时间(P<0.05)。COX回归分析结果表明,肿瘤TNM分期、淋巴转移和Pax9表达对非小细胞肺癌患者预后具有显著意义(P<0.05)。结论 Pax9在肺癌的发生发展中起一定作用,检测其血清含量对NSCLC的诊断具有重要的临床意义,其在血清中的过高表达有可能作为肺癌不良预后的评估指标。
Objective To investigate the expression and clinical significance of Pax9 gene in the serum of patients with non-small cell lung cancer (NSCLC). Methods Serum concentrations of Pax9 in 35 patients with NSCLC were determined by enzyme-linked immunosorbent assay (ELISA). The expression of Pax9 in 42 patients with benign lung disease (COPD, pneumonia) and 30 healthy controls were analyzed. Relationship with clinicopathological features and prognosis in NSCLC patients. Results The serum concentration of Pax9 in NSCLC patients was significantly higher than that in benign lung patients [(94.8 ± 44.4) ng / ml and (103.3 ± 58.3) ng / ml, respectively. There was statistical significance (P <0.05). The expression level of Pax9 was not related to clinicopathological characteristics such as sex, age, smoking history and lymphatic metastasis (P> 0.05), but significantly correlated with tumor pathological type and TNM stage (P <0.05). In addition, Kaplan-Meier analysis showed that the survival time of Pax9 high expression group was significantly lower than that of low expression group (P <0.05). The results of COX regression analysis showed that TNM staging, lymph node metastasis and Pax9 expression in non-small cell lung cancer patients have significant prognostic significance (P <0.05). Conclusion Pax9 plays a role in the development and progression of lung cancer. Detecting the serum level of Pax9 has important clinical significance in the diagnosis of NSCLC. Overexpression of Pax9 in serum may be used as an index to evaluate the prognosis of lung cancer.